Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0JGJDN)
| ADC Name |
HBM9033
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
HBM9033; YL215; PF-08052666; SGN-MesoC2; MesoC2
Click to Show/Hide
|
|||||
| Organization |
Harbour BioMed (Originator) (No Rights);MediLink Therapeutics (Originator) (No Rights);Seagen (Top20 MNC)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-MSLN antibody
|
Antibody Info | ||||
| Antigen Name |
Mesothelin (MSLN)
|
Antigen Info | ||||
| Payload Name |
YL0010014
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
VK*G-NHCH2-O linker
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Combination Type |
pelitecan
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Colorectal cancer | ||||
| Pancreatic cancer | ||||
| Lung cancer | ||||
| Pleura mesothelioma | ||||
| Ovarian cancer | ||||
| Endometrial cancer | ||||
| Unspecific solid tumor |